ACTA1 and pulmonary fibrosis: Montelukast, a potent cysteinylleukotriene1 (CysLT1) receptor antagonist, is therapeutically effective for the alleviation of further progression of lung fibrosis via the inhibition of α-smooth muscle actin (α-SMA).